May 21, 2025 — Gulf South Angels, a New Orleans-based venture investment group, said Tuesday that it plans to invest in South Rampart Pharma, a local startup that is trialing a new drug it hopes will be a breakthrough in the burgeoning market for non-opioid pain treatments.
South Rampart’s main drug — called SRP-001 while it is in the trial stage — has successfully passed through the first phase of Food and Drug Administration clinical trials and has been granted permission to fast-track Phase Two trials, which will be conducted with larger groups of humans.